Modeling Principle

The Mouse SiHa Model is an internationally recognized gold-standard in vivo model for researching malignant progression, invasion and metastasis, EMT transformation, and chemoradiotherapy tolerance of human HPV-16-positive cervical squamous cell carcinoma. Derived from primary human cervical squamous cell carcinoma, SiHa cells stably integrate the HPV-16 genome and present typical pathological features of clinical cervical squamous cell carcinoma with abnormal expression of p53 and pRB tumor suppressor genes, serving as the most classic and phenotypically stable benchmark cell line for cervical epithelial malignant tumors. Compared with other cervical cancer cell lines, SiHa cells exhibit typical epithelial morphology, stable proliferation, significant EMT activation and high in vivo tumorigenesis consistency, as well as inherent radioresistance and chemoresistance, which faithfully recapitulate the malignant progression of high-risk HPV-related cervical squamous cell carcinoma, including persistent proliferation, local invasion, early infiltration and postoperative recurrence. With stable adherent growth, negligible batch variation and high mycoplasma-negative rate, SiHa cells are widely utilized in research on viral carcinogenesis mechanisms, targeted pathway regulation, chemoradiotherapy sensitization, invasion-metastasis blockade and novel anti-tumor drug screening. Logarithmic-phase low-passage SiHa cells are subcutaneously inoculated into BALB/c-nu immunodeficient nude mice to establish standardized subcutaneous xenograft models with high tumorigenicity, strong phenotypic fidelity and excellent data reproducibility, fully meeting the standardized methodological writing requirements of NSFC projects, postgraduate proposals, dissertations and high-score SCI manuscripts.

Model Validation Criteria

Quantitative Criteria for Tumor Formation and Growth

1. Positive modeling criteria: Clear subcutaneous tumor nodules appear 4–6 days after SiHa cell inoculation. The tumor take rate is ≥95% within 10 days, and tumor volume ＞50 mm³ is defined as successful modeling. Tumors in the vehicle control group grow rapidly and continuously without spontaneous regression, which is completely consistent with the core characteristics of persistent proliferation and malignant progression of clinical HPV-positive cervical squamous cell carcinoma.

2. Reproducibility criteria: The intra‑group coefficient of variation (CV) of tumor volume in the vehicle group is ＜30%, indicating good modeling uniformity and low systematic error, which strictly meets SCI quality control requirements for data repeatability.

3. Pharmacodynamic response criteria: First-line cervical cancer positive drug intervention achieves TGI≥40% with significantly reduced tumor volume and weight compared with the control group (P＜0.05). The model presents stable and sensitive responses to chemotherapeutic drugs, targeted inhibitors and chemoradiotherapy sensitizers, enabling accurate evaluation of anti-proliferation, anti-invasion and chemoradiotherapy sensitization effects on cervical squamous cell carcinoma.

Histopathological and Molecular Gold-Standard Indexes

1. HE gold standard: Tumor tissues consist of a large number of atypical cervical squamous cancer cells with inconsistent cell size and morphology, large deeply stained nuclei, abundant mitotic figures, disordered cell arrangement and abnormal keratinization, which conform to the typical pathological morphological characteristics of human cervical squamous cell carcinoma.

2. Molecular phenotypic criteria: High Ki‑67 expression in tumor tissues indicates strong proliferative activity; high expression of Vimentin, N-cadherin, MMP2 and MMP9 combined with low E‑cadherin expression confirms significant EMT activation and high invasion-metastasis phenotype, while stably retaining core molecular characteristics of HPV-16 positivity and abnormal p53/pRB expression, which highly recapitulate the pathological mechanism of malignant progression of clinical high-risk HPV-driven cervical squamous cell carcinoma.

3. Pharmacodynamic response criteria: Treatment groups show down-regulated Ki‑67 expression, up-regulated Cleaved‑Caspase‑3, recovered E‑cadherin and reduced expression of Vimentin/N-cadherin/MMP2/MMP9, confirming that drugs can effectively inhibit cervical cancer proliferation, promote apoptosis, reverse EMT, block invasion and metastasis, and sensitize chemoradiotherapy.

4. Evidence closed‑loop criteria: In vivo tissue detection results are highly consistent with in vitro SiHa cell mechanistic experiments, forming a complete and credible evidence chain of targeted intervention mechanisms.

Academic Evidence for Model Validity

The Mouse SiHa Model is an internationally recognized gold-standard in vivo model for research on malignant progression, EMT invasion and metastasis, chemoradiotherapy tolerance and targeted sensitization of high-risk HPV-16-driven cervical squamous cell carcinoma. Core validity evidence: ① SiHa cells stably integrate the HPV-16 genome and carry the core pathogenic background of clinical high-risk cervical cancer, with abnormal p53/pRB pathways highly consistent with clinical carcinogenic mechanisms; ② It presents high in vivo tumor formation rate, typical tumor pathological phenotype and stable malignant progression, accurately simulating the pathological characteristics of continuous proliferation, local infiltration, recurrence and metastasis of clinical cervical squamous cell carcinoma; ③ It has clear gradient pharmacodynamic responses to targeted drugs, chemotherapy sensitizers and radiotherapy sensitizers, suitable for translational medicine and innovative drug research and development of cervical cancer; ④ It covers multi-dimensional mechanisms including HPV carcinogenic pathways, proliferation and apoptosis, EMT invasion and chemoradiotherapy resistance with wide research coverage and in-depth mechanism exploration potential; ⑤ It has been widely accepted by SCI journals in the fields of gynecological oncology and viral carcinogenesis for decades. As a core benchmark model for basic and translational research of cervical squamous cell carcinoma, it is applicable for methodology construction of various projects, research proposals and high-score papers.

Model Advantages

The Mouse SiHa Model is an exclusive SCI gold-standard model for targeted therapy, chemoradiotherapy sensitization and invasion-metastasis mechanism research of high-risk HPV-16-positive cervical squamous cell carcinoma. Core advantages: It accurately corresponds to the most clinically harmful high-risk HPV-related cervical squamous cell carcinoma with clear viral carcinogenic background and stable abnormal p53/pRB pathway phenotypes, showing higher clinical compatibility than other cervical cancer cell lines. It features stable in vivo tumorigenesis, homogeneous proliferation and minimal batch variation with high signal-to-noise ratio and strong data reproducibility, suitable for in-depth mechanism exploration of high-score papers and innovative design of NSFC projects. It inherently possesses high EMT activation, strong local invasion and mild chemoradiotherapy tolerance phenotypes, perfectly simulating the malignant characteristics of invasive growth and postoperative easy recurrence of clinical cervical squamous cell carcinoma. It can accurately carry out multi-dimensional research including HPV carcinogenic mechanism, targeted intervention, chemoradiotherapy sensitization and anti-invasion and metastasis. It forms a complete gynecological tumor research system with the group’s multi-tumor models covering ovarian cancer, cervical cancer and other tumors, with strong systematicness and outstanding innovation, enjoying excellent recognition in SCI manuscripts and fund applications.

Research Applications

The Mouse SiHa Model is mainly applied to preclinical mechanism and translational research on viral carcinogenic mechanisms, malignant proliferation, EMT invasion and metastasis, chemoradiotherapy tolerance and targeted sensitization of high-risk HPV-16-positive cervical squamous cell carcinoma. Core application scenarios: molecular mechanism analysis of high-risk HPV-mediated cervical carcinogenesis; research on tumor malignant progression driven by abnormal p53/pRB pathways; in-vivo efficacy evaluation of innovative drugs for targeted tumor suppression, EMT reversal and invasion-metastasis blockade; mechanism exploration of chemoradiotherapy sensitization, toxicity reduction, efficacy enhancement and treatment resistance overcoming in cervical cancer. It fills the research gap of standardized animal models for high-risk HPV-related cervical squamous cell carcinoma, fully supports innovative mechanism exploration for NSFC and provincial-level projects, postgraduate proposals, dissertations and high-score SCI papers in gynecological oncology, serving as an indispensable core gold-standard in-vivo model for basic and targeted translational research of HPV-positive cervical squamous cell carcinoma.

SiHa cell, human cervical squamous cell carcinoma, cervical cancer, HPV-16 positive, p53/pRB abnormality, epithelial malignant tumor, high invasion and metastasis, radioresistance, EMT activation, subcutaneous xenograft model, cervical cancer targeted therapy, preclinical efficacy evaluation